AU2-94 / Aucentra - LARVOL DELTA

CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer. (PubMed, J Exp Clin Cancer Res) - "These findings establish selective CDK4 inhibition as a therapeutically active and mechanistically rational strategy in prostate cancer and support AU2-94 as a candidate for further preclinical and clinical development, including in combination regimens for advanced and therapy-resistant disease."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • E2F1 • FOXM1

AU2-94: A CDK4-specific inhibitor with the marked anti-tumor efficacy (AACR 2024) - "This selectivity can be a reason for the better safety of AU2-94 compared to the clinical CDK4/6 inhibitors. The high oral bioavailability, robust antitumor efficacy and excellent safety profiles make AU2-94 a highly attractive candidate for clinical development."

Clinical • IO biomarker • Brain Cancer • Breast Cancer • CNS Tumor • Colorectal Cancer • Estrogen Receptor Positive Breast Cancer • Gastrointestinal Cancer • Glioblastoma • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BCL2 • CCNA2 • CCNB1 • CCNE2 • CDK2 • CDKN2A • CDKN2B • FOXM1 • KRAS

A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. (PubMed, Invest New Drugs) - "These findings support the repurposing of AU2-94 as a myeloprotective agent, highlighting its therapeutic potential in RB-deficient tumours. With AU2-94 advancing to clinical trials, these results underscore its broader therapeutic promise, extending to both RB-positive and RB-negative cancer treatment."

Journal • Breast Cancer • Eye Cancer • Hematological Disorders • Oncology • Retinal Disorders • Retinoblastoma • Solid Tumor • Triple Negative Breast Cancer